CDXS
Codexis Reports Robust Q4 2025 Financials, Outlines Ambitious RNA Medicine Strategy
San Francisco-based biotechnology company Codexis has reported strong fourth-quarter and fiscal year 2025 financial results, with the company's focus on RNA medicine gaining significant momentum. In a conference call to discuss the Q4 2025 earnings, Dr. Alison Moore, President and CEO of Codexis, highlighted the company's